Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 219 (ZNF219) is a Kruppel-like zinc finger protein that contains nine C2H2-type zinc finger domains and acts as a transcription factor in humans[1][3]. ZNF219 generally functions as a context-dependent regulator of gene transcription, acting as a transcriptional repressor for some targets such as high mobility group nucleosome binding domain 1 (HMGN1), and as a transcriptional activator in complex with other proteins, notably enhancing SOX9-mediated chondrogenic gene expression[1][3]. ZNF219 recognizes and binds to specific DNA sequences (e.g., GGGGG and CCCCCA motifs), can be localized in the nucleus, and participates in the regulation of genes important for cartilage development and potentially other developmental processes[1][2][3]. Disease associations include frontonasal dysplasia 1 and multiple epiphyseal dysplasia[3]. There are no direct reports of small molecule drugs or therapeutic agents specifically targeting ZNF219, and its primary described function is in gene regulation, not as a classical therapeutic target such as a receptor or enzyme[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 219 (ZNF219).